The authors of this preliminary study would like to post an update concerning our results. Our LSTM model identified the controversial and recently politicized drug, chloroquine; it’s ranked at 8th place, above Ribavirin, one of the drugs we focus attention towards due to positive clinical findings published in a recent article in The Lancet.
Today, May 22, The Lancet published another study by Mehra et al. (link appears below) that observed chloroquine and hydroxychloroquine had no notable therapeutic benefit in treating COVID-19. Some previous in-vitro studies and anecdotal observations suggested these drugs may have antiviral properties against SARS-CoV-2. Together, these observations remind us that in-silico and in-vitro analyses can provide valuable information, but definitive clinical assessments are best based on the gold standard of randomized clinical trials.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext